AstraZeneca to Cut 1600 Jobs
On March 18, 2013, AstraZeneca (AZ) announced that it will consolidate its Research & Development operations and as a result, 1600 jobs will be lost globally by 2016, with a majority in the U.S. and UK. AZ plans to invest in research centers in the UK, U.S. and Sweden “to improve pipeline productivity and to establish the company as a global leader in biopharmaceutical innovation.”
AZ’s subsidiary MedImmune’s HQ and the primary location for AstraZeneca’s biologics activities, will be the big U.S. winner as a result of these changes. Gaithersburg, Maryland will become the center of much of AZ’s U.S.-based global medicines development activities for small and large molecules and will accommodate some global marketing and U.S. specialty-care commercial functions — activities formerly housed in Wilmington.